medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/ms2025-378medsovet-9426Research ArticleЗАБОЛЕВАНИЯ КОЖИDERMAL DISEASESДупилумаб при атопическом дерматите: обзор данных и опыт примененияDupilumab in atopic dermatitis: Review of data and clinical experiencehttps://orcid.org/0000-0001-5723-6573ЖуковаО. В.ZhukovaO. V.

Жукова Ольга Валентиновна - д.м.н., профессор, заведующая кафедрой дерматовенерологии, аллергологии и косметологии Медицинского института, РУДН имени Патриса Лумумбы; главный врач, Московский НПЦ дерматовенерологии и косметологии;

117198, Москва, ул. Миклухо-Маклая, д. 6; 119071, Москва, Ленинский проспект, д. 17

Olga V. Zhukova - Dr. Sci. (Med.), Professor, Head of the Department of Dermatovenereology, Allergology and Cosmetology, Medical Institute, PFUR named after Patrice Lumumba; Chief Medical Officer, Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology.

6, Miklukho-Maklai St., Moscow, 117198; 17, Leninsky Ave., Moscow, 119071

klinderma@inbox.ruhttps://orcid.org/0000-0002-2793-8862АртемьеваС. И.ArtemyevaS. I.

Артемьева Софья Иосифовна - ассистент кафедры дерматовенерологии, аллергологии и косметологии Медицинского института; РУДН имени Патриса Лумумбы; научный сотрудник отдела клинической дерматовенерологии и косметологии, врач-дерматовенеролог, Московский НПЦ дерматовенерологии и косметологии.

117198, Москва, ул. Миклухо-Маклая, д. 6; 119071, Москва, Ленинский проспект, д. 17

Sofya I. Artemyeva - Assistant of the Department of Dermatovenereology, Allergology and Cosmetology, Medical Institute, PFUR named after Patrice Lumumba; Researcher of the Department of Clinical Dermatovenereology and Cosmetology, Dermatovenerologist, Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology.

6, Miklukho-Maklai St., Moscow, 117198; 17, Leninsky Ave., Moscow, 119071

sofya.chern@gmail.comРоссийский университет дружбы народов имени Патриса Лумумбы; Московский научно-практический центр дерматовенерологии и косметологииРоссияPeoples’ Friendship University of Russia named after Patrice Lumumba; Moscow Scientific and Practical Center of Dermatovenereology and CosmetologyRussian Federation202530092025014116124Copyright © Жукова О.В., Артемьева С.И., 20252025Жукова О.В., Артемьева С.И.Zhukova O.V., Artemyeva S.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/9426Введение

Введение. Атопический дерматит (АтД) – хроническое воспалительное заболевание кожи, существенно влияющее на качество жизни пациентов. Появление таргетной биологической терапии дупилумабом стало важным этапом в лечении среднетяжелого и тяжелого АтД, что подтверждено клиническими исследованиями и данными реальной клинической практики. Цель. Изучить динамику качества жизни у пациентов с АтД, получающих дупилумаб, в реальной клинической практике.

Материалы и методы

Материалы и методы. Проведен обзор современной литературы, включающей результаты клинических исследований и регистровых данных, а также анализ собственной выборки из 38 пациентов с АтД, получавших терапию дупилумабом. Оценивалась динамика клинических индексов (EASI, SCORAD, VAS) и показатели качества жизни (DLQI – у взрослых и CDLQI – у детей).

Результаты

Результаты. Возраст пациентов варьировал от 6 до 47 лет (средний – 20 лет), мужчины составили 65,8%. Продолжительность терапии составляла от 2 до 5 лет (в среднем – 3,4 года). На фоне лечения средний индекс EASI снизился с 39,0 до 5,2 (p < 0,0001), SCORAD – с 58,7 до 11,2 (p < 0,0001), VAS – с 7,3 до 2,2 (p < 0,0001). Показатели качества жизни улучшились: DLQI снизился с 25,1 до 2,3, CDLQI – с 21,1 до 2,4 (оба p < 0,00001). Полученные данные согласуются с международными исследованиями (TREATgermany, BioDay, RELIEVE-AD).

Выводы

Выводы. Дупилумаб демонстрирует высокую эффективность, значимое снижение клинических проявлений и улучшение качества жизни у взрослых и детей с АтД при длительном применении в реальной клинической практике. Сочетание данных рандомизированных исследований и реальной практики подтверждает, что дупилумаб является препаратом выбора и может рассматриваться как оптимальная долгосрочная терапевтическая стратегия для пациентов с АтД.

Introduction

Introduction. Atopic dermatitis (AD) is a chronic inflammatory skin disease that significantly impairs patients’ quality of life. The advent of targeted biologic therapy with dupilumab has become an important milestone in the treatment of moderate-to-severe AD, as confirmed by clinical trials and real-world data.

Aim

Aim. To study the dynamics of quality of life in patients with AD receiving dupilumab in real clinical practice.

Materials and methods

Materials and methods. A review of current literature, including results from clinical trials and registry data, was conducted, along with an analysis of our own cohort of 38 patients with AD treated with dupilumab. The dynamics of clinical indices (EASI, SCORAD, VAS) and quality-of-life measures (DLQI in adults and CDLQI in children) were evaluated.

Results

Results. Patients’ ages ranged from 6 to 47 years (mean – 20 years), with males accounting for 65.8%. The duration of therapy ranged from 2 to 5 years (mean – 3.4 years). During treatment, the mean EASI score decreased from 39.0 to 5.2 (p < 0.0001), SCORAD from 58.7 to 11.2 (p < 0.0001), and VAS from 7.3 to 2.2 (p < 0.0001). Quality-of-life measures improved markedly: DLQI decreased from 25.1 to 2.3, and CDLQI from 21.1 to 2.4 (both p < 0.00001). These findings are consistent with international studies such as TREATgermany, BioDay, and RELIEVE-AD.

Conclusion

Conclusion. Dupilumab demonstrates high efficacy, significant reduction in clinical manifestations, and substantial improvement in quality of life in both adults and children with AD during long-term real-world use. The combination of evidence from randomized clinical trials and real-world practice confirms that dupilumab is the treatment of choice and may be considered an optimal long-term therapeutic strategy for patients with AD.

атопический дерматитдупилумабГИБТкачество жизнибезопасность терапииatopic dermatitisdupilumabbiologic therapyquality of lifetreatment safetyReferencesBylund S, Kobyletzki LB, Svalstedt M, Svensson Å. Prevalence and Incidence of Atopic Dermatitis: A Systematic Review. Acta Derm Venereol. 2020;100(12):320–329. https://doi.org/10.2340/00015555-3510.Bylund S, Kobyletzki LB, Svalstedt M, Svensson Å. Prevalence and Incidence of Atopic Dermatitis: A Systematic Review. Acta Derm Venereol. 2020;100(12):320–329. https://doi.org/10.2340/00015555-3510.Augustin M, Langenbruch A, Blome C, Gutknecht M, Werfel T, Ständer S et al. Characterizing treatment-related patient needs in atopic eczema: insights for personalized goal orientation. J Eur Acad Dermatol Venereol. 2020;34(1):142–152. https://doi.org/10.1111/jdv.15919.Augustin M, Langenbruch A, Blome C, Gutknecht M, Werfel T, Ständer S et al. Characterizing treatment-related patient needs in atopic eczema: insights for personalized goal orientation. J Eur Acad Dermatol Venereol. 2020;34(1):142–152. https://doi.org/10.1111/jdv.15919.Rønnstad ATM, Halling-Overgaard AS, Hamann CR, Skov L, Egeberg A, Thyssen JP. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis. J Am Acad Dermatol. 2018;79(3):448–456. https://doi.org/10.1016/j.jaad.2018.03.017.Rønnstad ATM, Halling-Overgaard AS, Hamann CR, Skov L, Egeberg A, Thyssen JP. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis. J Am Acad Dermatol. 2018;79(3):448–456. https://doi.org/10.1016/j.jaad.2018.03.017.Laughter MR, Maymone MBC, Mashayekhi S, Arents BWM, Karimkhani C, Langan SM et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017. Br J Dermatol. 2021;184(2):304–309. https://doi.org/10.1111/bjd.19580.Laughter MR, Maymone MBC, Mashayekhi S, Arents BWM, Karimkhani C, Langan SM et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017. Br J Dermatol. 2021;184(2):304–309. https://doi.org/10.1111/bjd.19580.Guttman-Yassky E, Bissonnette R, Ungar B, Suárez-Fariñas M, Ardeleanu M, Esaki H et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):155–172. https://doi.org/10.1016/j.jaci.2018.08.022.Guttman-Yassky E, Bissonnette R, Ungar B, Suárez-Fariñas M, Ardeleanu M, Esaki H et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):155–172. https://doi.org/10.1016/j.jaci.2018.08.022.Harb H, Chatila TA. Mechanisms of Dupilumab. Clin Exp Allergy. 2020;50(1):5–14. https://doi.org/10.1111/cea.13491.Harb H, Chatila TA. Mechanisms of Dupilumab. Clin Exp Allergy. 2020;50(1):5–14. https://doi.org/10.1111/cea.13491.Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303. https://doi.org/10.1016/S0140-6736(17)31191-1.Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303. https://doi.org/10.1016/S0140-6736(17)31191-1.Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016;375(24):2335–2348. https://doi.org/10.1056/NEJMoa1610020.Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016;375(24):2335–2348. https://doi.org/10.1056/NEJMoa1610020.Wollenberg A, Kinberger M, Arents B, Aszodi N, Barbarot S, Bieber T et al. European Guideline (EuroGuiDerm) on atopic eczema: Living update. J Eur Acad Dermatol Venereol. 2025;39(9):1537–1566. https://doi.org/10.1111/jdv.20639.Wollenberg A, Kinberger M, Arents B, Aszodi N, Barbarot S, Bieber T et al. European Guideline (EuroGuiDerm) on atopic eczema: Living update. J Eur Acad Dermatol Venereol. 2025;39(9):1537–1566. https://doi.org/10.1111/jdv.20639.Mortato E, Talamonti M, Paganini C, Belcastro A, Tofani L, Bianchi L, Galluzzo M. Could Disease Duration Influence Response to Dupilumab in Patients With Atopic Dermatitis? A Retrospective Real-Life Study. Int J Dermatol. 2025. https://doi.org/10.1111/ijd.17939.Mortato E, Talamonti M, Paganini C, Belcastro A, Tofani L, Bianchi L, Galluzzo M. Could Disease Duration Influence Response to Dupilumab in Patients With Atopic Dermatitis? A Retrospective Real-Life Study. Int J Dermatol. 2025. https://doi.org/10.1111/ijd.17939.Zeidler C, Tsianakas A, Pereira M, Ständer H, Yosipovitch G, Ständer S. Chronic Prurigo of Nodular Type: A Review. Acta Derm Venereol. 2018;98(2):173–179. https://doi.org/10.2340/00015555-2774.Zeidler C, Tsianakas A, Pereira M, Ständer H, Yosipovitch G, Ständer S. Chronic Prurigo of Nodular Type: A Review. Acta Derm Venereol. 2018;98(2):173–179. https://doi.org/10.2340/00015555-2774.Yosipovitch G, Kwatra ShG, Mollanazar N, Ständer S, Satoh T, Laws E et al. 344 Dupilumab significantly improves itch and skin lesions in patients with prurigo nodularis: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2). Br J Derm. 2023;188(Suppl. 2):ljac140.038. https://doi.org/10.1093/bjd/ljac140.038.Yosipovitch G, Kwatra ShG, Mollanazar N, Ständer S, Satoh T, Laws E et al. 344 Dupilumab significantly improves itch and skin lesions in patients with prurigo nodularis: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2). Br J Derm. 2023;188(Suppl. 2):ljac140.038. https://doi.org/10.1093/bjd/ljac140.038.Gilhar A, Laufer-Britva R, Keren A, Paus R. Frontiers in alopecia areata pathobiology research. J Allergy Clin Immunol. 2019;144(6):1478–1489. https://doi.org/10.1016/j.jaci.2019.08.035.Gilhar A, Laufer-Britva R, Keren A, Paus R. Frontiers in alopecia areata pathobiology research. J Allergy Clin Immunol. 2019;144(6):1478–1489. https://doi.org/10.1016/j.jaci.2019.08.035.Renert-Yuval Y, Pavel AB, Del Duca E, Facheris P, Pagan AD, Bose S et al. Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata. Allergy. 2023;78(4):1047–1059. https://doi.org/10.1111/all.15561.Renert-Yuval Y, Pavel AB, Del Duca E, Facheris P, Pagan AD, Bose S et al. Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata. Allergy. 2023;78(4):1047–1059. https://doi.org/10.1111/all.15561.Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139. https://doi.org/10.1056/NEJMoa1314768.Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139. https://doi.org/10.1056/NEJMoa1314768.Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebocontrolled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40–52. https://doi.org/10.1016/S0140-6736(15)00388-8.Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebocontrolled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40–52. https://doi.org/10.1016/S0140-6736(15)00388-8.Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459–473. https://doi.org/10.1111/bjd.17869.Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459–473. https://doi.org/10.1111/bjd.17869.Foley P, Kerdraon YA, Hogden JP, Shumack S, Spelman L, Sebaratnam DF et al. Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting. Australas J Dermatol. 2022;63(4):421–436. https://doi.org/10.1111/ajd.13924.Foley P, Kerdraon YA, Hogden JP, Shumack S, Spelman L, Sebaratnam DF et al. Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting. Australas J Dermatol. 2022;63(4):421–436. https://doi.org/10.1111/ajd.13924.Wu D, Daniel BS, Lai AJX, Wong N, Lim DKA, Murrell DF et al. Dupilumabassociated ocular manifestations: A review of clinical presentations and management. Surv Ophthalmol. 2022;67(5):1419–1442. https://doi.org/10.1016/j.survophthal.2022.02.002.Wu D, Daniel BS, Lai AJX, Wong N, Lim DKA, Murrell DF et al. Dupilumabassociated ocular manifestations: A review of clinical presentations and management. Surv Ophthalmol. 2022;67(5):1419–1442. https://doi.org/10.1016/j.survophthal.2022.02.002.Achten R, Thijs J, van der Wal M, van Luijk C, de Graaf M, Bakker D et al. Dupilumab-associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis. Allergy. 2023;78(8):2266–2276. https://doi.org/10.1111/all.15717.Achten R, Thijs J, van der Wal M, van Luijk C, de Graaf M, Bakker D et al. Dupilumab-associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis. Allergy. 2023;78(8):2266–2276. https://doi.org/10.1111/all.15717.Ardern-Jones MR, Brown SJ, Flohr C, Hossain P, Irvine AD, Johnston GA et al. An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024. Br J Dermatol. 2024;191(6):865–885. https://doi.org/10.1093/bjd/ljae344.Ardern-Jones MR, Brown SJ, Flohr C, Hossain P, Irvine AD, Johnston GA et al. An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024. Br J Dermatol. 2024;191(6):865–885. https://doi.org/10.1093/bjd/ljae344.Chrétien B, Dolladille C, Alexandre J, Fedrizzi S, Lelong-Boulouard V, Lambert JC, Ezine E. Dupilumab-associated arthralgia: an observational retrospective study in VigiBase®. Br J Dermatol. 2021;185(2):464–465. https://doi.org/10.1111/bjd.20138.Chrétien B, Dolladille C, Alexandre J, Fedrizzi S, Lelong-Boulouard V, Lambert JC, Ezine E. Dupilumab-associated arthralgia: an observational retrospective study in VigiBase®. Br J Dermatol. 2021;185(2):464–465. https://doi.org/10.1111/bjd.20138.Jay R, Rodger J, Zirwas M. Review of dupilumab-associated inflammatory arthritis: An approach to clinical analysis and management. JAAD Case Rep. 2022;21:14–18. https://doi.org/10.1016/j.jdcr.2021.12.011.Jay R, Rodger J, Zirwas M. Review of dupilumab-associated inflammatory arthritis: An approach to clinical analysis and management. JAAD Case Rep. 2022;21:14–18. https://doi.org/10.1016/j.jdcr.2021.12.011.Woodbury MJ, Smith JS, Merola JF. Dupilumab-Associated Arthritis: A Dermatology-Rheumatology Perspective. Am J Clin Dermatol. 2023;24(6):859–864. https://doi.org/10.1007/s40257-023-00804-5.Woodbury MJ, Smith JS, Merola JF. Dupilumab-Associated Arthritis: A Dermatology-Rheumatology Perspective. Am J Clin Dermatol. 2023;24(6):859–864. https://doi.org/10.1007/s40257-023-00804-5.Napolitano M, Ruggiero A, Patruno C. Dupilumab-associated inflammatory arthritis: a literature review. Clin Exp Dermatol. 2024;49(4):307–312. https://doi.org/10.1093/ced/llad390.Napolitano M, Ruggiero A, Patruno C. Dupilumab-associated inflammatory arthritis: a literature review. Clin Exp Dermatol. 2024;49(4):307–312. https://doi.org/10.1093/ced/llad390.Napolitano M, Fabbrocini G, Patruno C. Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: A retrospective study. J Dermatol. 2023;50(7):880–887. https://doi.org/10.1111/1346-8138.16764.Napolitano M, Fabbrocini G, Patruno C. Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: A retrospective study. J Dermatol. 2023;50(7):880–887. https://doi.org/10.1111/1346-8138.16764.Napolitano M, Scalvenzi M, Fabbrocini G, Cinelli E, Patruno C. Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: A case series. Dermatol Ther. 2019;32(6):e13142. https://doi.org/10.1111/dth.13142.Napolitano M, Scalvenzi M, Fabbrocini G, Cinelli E, Patruno C. Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: A case series. Dermatol Ther. 2019;32(6):e13142. https://doi.org/10.1111/dth.13142.Maronese CA, Valenti M, Moltrasio C, Romagnuolo M, Ferrucci SM, Gilliet M et al. Paradoxical Psoriasis: An Updated Review of Clinical Features, Pathogenesis, and Treatment Options. J Invest Dermatol. 2024;144(11):2364–2376. https://doi.org/10.1016/j.jid.2024.05.015.Maronese CA, Valenti M, Moltrasio C, Romagnuolo M, Ferrucci SM, Gilliet M et al. Paradoxical Psoriasis: An Updated Review of Clinical Features, Pathogenesis, and Treatment Options. J Invest Dermatol. 2024;144(11):2364–2376. https://doi.org/10.1016/j.jid.2024.05.015.Grolleau C, Calugareanu A, Demouche S, Nosbaum A, Staumont-Sallé D, Aubert H et al. IL-4/IL-13 Inhibitors for Atopic Dermatitis Induce Psoriatic Rash Transcriptionally Close to Pustular Psoriasis. J Invest Dermatol. 2023;143(5):711–721. https://doi.org/10.1016/j.jid.2022.10.015.Grolleau C, Calugareanu A, Demouche S, Nosbaum A, Staumont-Sallé D, Aubert H et al. IL-4/IL-13 Inhibitors for Atopic Dermatitis Induce Psoriatic Rash Transcriptionally Close to Pustular Psoriasis. J Invest Dermatol. 2023;143(5):711–721. https://doi.org/10.1016/j.jid.2022.10.015.Trave I, Salvi I, Burlando M, Cozzani E, Parodi A. “De Novo” Psoriasis and Relapse of Psoriasis Induced by Dupilumab: Three New Cases and Review of the Literature. J Clin Med. 2023;12(19):6291. https://doi.org/10.3390/jcm12196291.Trave I, Salvi I, Burlando M, Cozzani E, Parodi A. “De Novo” Psoriasis and Relapse of Psoriasis Induced by Dupilumab: Three New Cases and Review of the Literature. J Clin Med. 2023;12(19):6291. https://doi.org/10.3390/jcm12196291.Jo CE, Finstad A, Georgakopoulos JR, Piguet V, Yeung J, Drucker AM. Facial and neck erythema associated with dupilumab treatment: A systematic review. J Am Acad Dermatol. 2021;84(5):1339–1347. https://doi.org/10.1016/j.jaad.2021.01.012.Jo CE, Finstad A, Georgakopoulos JR, Piguet V, Yeung J, Drucker AM. Facial and neck erythema associated with dupilumab treatment: A systematic review. J Am Acad Dermatol. 2021;84(5):1339–1347. https://doi.org/10.1016/j.jaad.2021.01.012.Bangert C, Alkon N, Chennareddy S, Arnoldner T, Levine JP, Pilz M et al. Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells. Nat Commun. 2024;15(1):2839. https://doi.org/10.1038/s41467-024-46540-0.Bangert C, Alkon N, Chennareddy S, Arnoldner T, Levine JP, Pilz M et al. Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells. Nat Commun. 2024;15(1):2839. https://doi.org/10.1038/s41467-024-46540-0.Eichenfield LF, Bieber T, Beck LA, Simpson EL, Thaçi D, de Bruin-Weller M et al. Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. Am J Clin Dermatol. 2019;20(3):443–456. https://doi.org/10.1007/s40257-019-00445-7.Eichenfield LF, Bieber T, Beck LA, Simpson EL, Thaçi D, de Bruin-Weller M et al. Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. Am J Clin Dermatol. 2019;20(3):443–456. https://doi.org/10.1007/s40257-019-00445-7.Blauvelt A, Wollenberg A, Eichenfield LF, Zhang H, Sierka D, Khokhar FA et al. No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab. Adv Ther. 2023;40(1):367–380. https://doi.org/10.1007/s12325-022-02322-y.Blauvelt A, Wollenberg A, Eichenfield LF, Zhang H, Sierka D, Khokhar FA et al. No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab. Adv Ther. 2023;40(1):367–380. https://doi.org/10.1007/s12325-022-02322-y.Pera V, Brusselle GG, Riemann S, Kors JA, Van Mulligen EM, Parry R et al. Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration’s adverse event reporting system (FAERS). Front Pharmacol. 2023;14:1276340. https://doi.org/10.3389/fphar.2023.1276340.Pera V, Brusselle GG, Riemann S, Kors JA, Van Mulligen EM, Parry R et al. Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration’s adverse event reporting system (FAERS). Front Pharmacol. 2023;14:1276340. https://doi.org/10.3389/fphar.2023.1276340.Gill K, Xu J, Kozera E, Stewart T, Flora A, Frew JW. Strongyloides screening prior to dupilumab therapy in atopic dermatitis: a retrospective cohort study evaluating screening utility. Br J Dermatol. 2023;188(2):294–295. https://doi.org/10.1093/bjd/ljac060.Gill K, Xu J, Kozera E, Stewart T, Flora A, Frew JW. Strongyloides screening prior to dupilumab therapy in atopic dermatitis: a retrospective cohort study evaluating screening utility. Br J Dermatol. 2023;188(2):294–295. https://doi.org/10.1093/bjd/ljac060.Ramanathan R, Nutman T. Strongyloides stercoralis infection in the immunocompromised host. Curr Infect Dis Rep. 2008;10(2):105–110. https://doi.org/10.1007/s11908-008-0019-6.Ramanathan R, Nutman T. Strongyloides stercoralis infection in the immunocompromised host. Curr Infect Dis Rep. 2008;10(2):105–110. https://doi.org/10.1007/s11908-008-0019-6.Kridin K, Abdelghaffar M, Bieber K, Thaci D, Ludwig RJ. The real-world, long-term risk of infections associated with dupilumab in atopic dermatitis: A global cohort study. J Eur Acad Dermatol Venereol. 2025. https://doi.org/10.1111/jdv.20724.Kridin K, Abdelghaffar M, Bieber K, Thaci D, Ludwig RJ. The real-world, long-term risk of infections associated with dupilumab in atopic dermatitis: A global cohort study. J Eur Acad Dermatol Venereol. 2025. https://doi.org/10.1111/jdv.20724.Paller AS, Ramien M, Cork MJ, Simpson EL, Wine Lee L, Eichenfield LF et al. Low Infection Rates With Long-Term Dupilumab Treatment in Patients Aged 6 Months to 5 Years: An Open-Label Extension Study. Pediatr Dermatol. 2025;42(2):251–258. https://doi.org/10.1111/pde.15781.Paller AS, Ramien M, Cork MJ, Simpson EL, Wine Lee L, Eichenfield LF et al. Low Infection Rates With Long-Term Dupilumab Treatment in Patients Aged 6 Months to 5 Years: An Open-Label Extension Study. Pediatr Dermatol. 2025;42(2):251–258. https://doi.org/10.1111/pde.15781.Johansson EK, Ivert LU, Bradley B, Lundqvist M, Bradley M. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study. BMC Dermatol. 2020;20(1):8. https://doi.org/10.1186/s12895-020-00103-0.Johansson EK, Ivert LU, Bradley B, Lundqvist M, Bradley M. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study. BMC Dermatol. 2020;20(1):8. https://doi.org/10.1186/s12895-020-00103-0.Nicolosi S, Barei F, Romagnuolo M, Fumagalli S, Marzano AV, Ferrucci SM. Does Body Mass Index Impact the Clinical Response to Dupilumab Therapy in Atopic Dermatitis? A Monocentric Study of 170 Patients. J Clin Med. 2024;13(15):4559. https://doi.org/10.3390/jcm13154559.Nicolosi S, Barei F, Romagnuolo M, Fumagalli S, Marzano AV, Ferrucci SM. Does Body Mass Index Impact the Clinical Response to Dupilumab Therapy in Atopic Dermatitis? A Monocentric Study of 170 Patients. J Clin Med. 2024;13(15):4559. https://doi.org/10.3390/jcm13154559.Tayefi M, Svedbom A, Ivert L, Lundqvist M, Ruas J, Bradley M, Johansson E. Risk Factors Associated with Weight Gain during Treatment with Dupilumab among Patients with Moderate to Severe Atopic Dermatitis. Acta Derm Venereol. 2024;104:adv40796. https://doi.org/10.2340/actadv.v104.40796.Tayefi M, Svedbom A, Ivert L, Lundqvist M, Ruas J, Bradley M, Johansson E. Risk Factors Associated with Weight Gain during Treatment with Dupilumab among Patients with Moderate to Severe Atopic Dermatitis. Acta Derm Venereol. 2024;104:adv40796. https://doi.org/10.2340/actadv.v104.40796.Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ et al. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2020;156(1):44–56. https://doi.org/10.1001/jamadermatol.2019.3336.Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ et al. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2020;156(1):44–56. https://doi.org/10.1001/jamadermatol.2019.3336.Wechsler ME, Klion AD, Paggiaro P, Nair P, Staumont-Salle D, Radwan A et al. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis. J Allergy Clin Immunol Pract. 2022;10(10):2695–2709. https://doi.org/10.1016/j.jaip.2022.05.019.Wechsler ME, Klion AD, Paggiaro P, Nair P, Staumont-Salle D, Radwan A et al. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis. J Allergy Clin Immunol Pract. 2022;10(10):2695–2709. https://doi.org/10.1016/j.jaip.2022.05.019.Kim PJ, Lansang RP, Vender R. A Systematic Review and Meta-Analysis of Injection Site Reactions in Randomized-Controlled Trials of Biologic Injections. J Cutan Med Surg. 2023;27(4):358–367. https://doi.org/10.1177/12034754231188444.Kim PJ, Lansang RP, Vender R. A Systematic Review and Meta-Analysis of Injection Site Reactions in Randomized-Controlled Trials of Biologic Injections. J Cutan Med Surg. 2023;27(4):358–367. https://doi.org/10.1177/12034754231188444.Treudler R, Delaroque N, Puder M, Simon JC, Szardenings M. Dupilumabinduced serum sickness-like reaction: an unusual adverse effect in a patient with atopic eczema. J Eur Acad Dermatol Venereol. 2021;35(1):e30–e32. https://doi.org/10.1111/jdv.16782.Treudler R, Delaroque N, Puder M, Simon JC, Szardenings M. Dupilumabinduced serum sickness-like reaction: an unusual adverse effect in a patient with atopic eczema. J Eur Acad Dermatol Venereol. 2021;35(1):e30–e32. https://doi.org/10.1111/jdv.16782.Jung JH, Shapero M, Kaplan B. Nonirritating skin test concentrations and a case of serum sickness to dupilumab. J Allergy Clin Immunol Pract. 2023;11(4):1314–1316. https://doi.org/10.1016/j.jaip.2022.12.036.Jung JH, Shapero M, Kaplan B. Nonirritating skin test concentrations and a case of serum sickness to dupilumab. J Allergy Clin Immunol Pract. 2023;11(4):1314–1316. https://doi.org/10.1016/j.jaip.2022.12.036.Ludriksone L, Elsner P, Schliemann S. Acquired hypersensitivity to dupilumab: first case report. J Eur Acad Dermatol Venereol. 2019;33(12):e482–e483. https://doi.org/10.1111/jdv.15807.Ludriksone L, Elsner P, Schliemann S. Acquired hypersensitivity to dupilumab: first case report. J Eur Acad Dermatol Venereol. 2019;33(12):e482–e483. https://doi.org/10.1111/jdv.15807.Preuß SL, Bieber K, Vorobyev A, Recke A, Moderegger EL, Zirpel H et al. Dupilumab shows no elevated risk for maternal adverse pregnancy outcomes: A propensity-matched cohort study. J Eur Acad Dermatol Venereol. 2025;39(9):1576–1587. https://doi.org/10.1111/jdv.20670.Preuß SL, Bieber K, Vorobyev A, Recke A, Moderegger EL, Zirpel H et al. Dupilumab shows no elevated risk for maternal adverse pregnancy outcomes: A propensity-matched cohort study. J Eur Acad Dermatol Venereol. 2025;39(9):1576–1587. https://doi.org/10.1111/jdv.20670.Gregoriou S, Routsi E, Koumprentziotis IA, Papapanou M, Stratigos A. Dupilumab use for atopic dermatitis during pregnancy: A systematic review. J Eur Acad Dermatol Venereol. 2025;39(9):e750–e755. https://doi.org/10.1111/jdv.20570.Gregoriou S, Routsi E, Koumprentziotis IA, Papapanou M, Stratigos A. Dupilumab use for atopic dermatitis during pregnancy: A systematic review. J Eur Acad Dermatol Venereol. 2025;39(9):e750–e755. https://doi.org/10.1111/jdv.20570.Vestergaard C, Deleuran M. Bridging the gap: Treatment of atopic dermatitis with dupilumab during pregnancy. J Eur Acad Dermatol Venereol. 2025;39(9):1527–1528. https://doi.org/10.1111/jdv.20832.Vestergaard C, Deleuran M. Bridging the gap: Treatment of atopic dermatitis with dupilumab during pregnancy. J Eur Acad Dermatol Venereol. 2025;39(9):1527–1528. https://doi.org/10.1111/jdv.20832.Wu H, Zhu J, Yang N, Ji X, Li Z, Zhou Y et al. Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab. J Dtsch Dermatol Ges. 2025;23(6):702–710. https://doi.org/10.1111/ddg.15688.Wu H, Zhu J, Yang N, Ji X, Li Z, Zhou Y et al. Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab. J Dtsch Dermatol Ges. 2025;23(6):702–710. https://doi.org/10.1111/ddg.15688.Peters AS, Kellberger J, Vogelberg C, Dressel H, Windstetter D, Weinmayr G et al. Prediction of the incidence, recurrence, and persistence of atopic dermatitis in adolescence: a prospective cohort study. J Allergy Clin Immunol. 2010;126(3):590–5.e53. https://doi.org/10.1016/j.jaci.2010.06.020.Peters AS, Kellberger J, Vogelberg C, Dressel H, Windstetter D, Weinmayr G et al. Prediction of the incidence, recurrence, and persistence of atopic dermatitis in adolescence: a prospective cohort study. J Allergy Clin Immunol. 2010;126(3):590–5.e53. https://doi.org/10.1016/j.jaci.2010.06.020.Vakharia PP, Silverberg JI. Adult-Onset Atopic Dermatitis: Characteristics and Management. Am J Clin Dermatol. 2019;20(6):771–779. https://doi.org/10.1007/s40257-019-00453-7.Vakharia PP, Silverberg JI. Adult-Onset Atopic Dermatitis: Characteristics and Management. Am J Clin Dermatol. 2019;20(6):771–779. https://doi.org/10.1007/s40257-019-00453-7.Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132(5):1132–1138. https://doi.org/10.1016/j.jaci.2013.08.031.Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132(5):1132–1138. https://doi.org/10.1016/j.jaci.2013.08.031.Masson Regnault M, Shourick J, Jendoubi F, Tauber M, Paul C. Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review. Am J Clin Dermatol. 2022;23(4):433–447. https://doi.org/10.1007/s40257-02200679-y.Masson Regnault M, Shourick J, Jendoubi F, Tauber M, Paul C. Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review. Am J Clin Dermatol. 2022;23(4):433–447. https://doi.org/10.1007/s40257-02200679-y.Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J et al. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderateto-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). Am J Clin Dermatol. 2022;23(3):365–383. https://doi.org/10.1007/s40257-022-00683-2.Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J et al. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderateto-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). Am J Clin Dermatol. 2022;23(3):365–383. https://doi.org/10.1007/s40257-022-00683-2.Li H, Zhang Z, Zhang H, Guo Y, Yao Z. Update on the Pathogenesis and Therapy of Atopic Dermatitis. Clin Rev Allergy Immunol. 2021;61(3):324–338. https://doi.org/10.1007/s12016-021-08880-3.Li H, Zhang Z, Zhang H, Guo Y, Yao Z. Update on the Pathogenesis and Therapy of Atopic Dermatitis. Clin Rev Allergy Immunol. 2021;61(3):324–338. https://doi.org/10.1007/s12016-021-08880-3.Bakker DS, van der Wal MM, Heeb LEM, Giovannone B, Asamoah M, Delemarre EM et al. Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis. J Invest Dermatol. 2021;141(8):1943–1953. https://doi.org/10.1016/j.jid.2021.01.022.Bakker DS, van der Wal MM, Heeb LEM, Giovannone B, Asamoah M, Delemarre EM et al. Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis. J Invest Dermatol. 2021;141(8):1943–1953. https://doi.org/10.1016/j.jid.2021.01.022.Mohamed MF, Bhatnagar S, Parmentier JM, Nakasato P, Wung P. Upadacitinib: Mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17(1):e13688. https://doi.org/10.1111/cts.13688.Mohamed MF, Bhatnagar S, Parmentier JM, Nakasato P, Wung P. Upadacitinib: Mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17(1):e13688. https://doi.org/10.1111/cts.13688.Callewaert C, Nakatsuji T, Knight R, Kosciolek T, Vrbanac A, Kotol P et al. IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis. J Invest Dermatol. 2020;140(1):191–202. https://doi.org/10.1016/j.jid.2019.05.024.Callewaert C, Nakatsuji T, Knight R, Kosciolek T, Vrbanac A, Kotol P et al. IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis. J Invest Dermatol. 2020;140(1):191–202. https://doi.org/10.1016/j.jid.2019.05.024.Greenzaid JD, Chan LJ, Chandani BM, Kiritsis NR, Feldman SR. Microbiome modulators for atopic eczema: a systematic review of experimental and investigational therapeutics. Expert Opin Investig Drugs. 2024;33(4):415–430. https://doi.org/10.1080/13543784.2024.2326625.Greenzaid JD, Chan LJ, Chandani BM, Kiritsis NR, Feldman SR. Microbiome modulators for atopic eczema: a systematic review of experimental and investigational therapeutics. Expert Opin Investig Drugs. 2024;33(4):415–430. https://doi.org/10.1080/13543784.2024.2326625.Bangert C, Rindler K, Krausgruber T, Alkon N, Thaler FM, Kurz H et al. Persistence of mature dendritic cells, TH2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4Rα blockade. Sci Immunol. 2021;6(55):eabe2749. https://doi.org/10.1126/sciimmunol.abe2749.Bangert C, Rindler K, Krausgruber T, Alkon N, Thaler FM, Kurz H et al. Persistence of mature dendritic cells, TH2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4Rα blockade. Sci Immunol. 2021;6(55):eabe2749. https://doi.org/10.1126/sciimmunol.abe2749.Renert-Yuval Y, Del Duca E, Pavel AB, Fang M, Lefferdink R, Wu J et al. The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults. J Allergy Clin Immunol. 2021;148(1):148–163. https://doi.org/10.1016/j.jaci.2021.01.001.Renert-Yuval Y, Del Duca E, Pavel AB, Fang M, Lefferdink R, Wu J et al. The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults. J Allergy Clin Immunol. 2021;148(1):148–163. https://doi.org/10.1016/j.jaci.2021.01.001.Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273–282. https://doi.org/10.1016/S0140-6736(22)01199-0.Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273–282. https://doi.org/10.1016/S0140-6736(22)01199-0.Armario-Hita JC, Galán-Gutiérrez M, Dodero-Anillo JM, Carrascosa JM, Ruiz-Villaverde R. Updated Review on Treatment of Atopic Dermatitis. J Investig Allergol Clin Immunol. 2023;33(3):158–167. https://doi.org/10.18176/jiaci.0906.Armario-Hita JC, Galán-Gutiérrez M, Dodero-Anillo JM, Carrascosa JM, Ruiz-Villaverde R. Updated Review on Treatment of Atopic Dermatitis. J Investig Allergol Clin Immunol. 2023;33(3):158–167. https://doi.org/10.18176/jiaci.0906.Guttman-Yassky E, Silverberg JI, Thaçi D, Papp KA, Ständer S, Beck LA et al. Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial. J Eur Acad Dermatol Venereol. 2023;37(12):2558–2568. https://doi.org/10.1111/jdv.19391.Guttman-Yassky E, Silverberg JI, Thaçi D, Papp KA, Ständer S, Beck LA et al. Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial. J Eur Acad Dermatol Venereol. 2023;37(12):2558–2568. https://doi.org/10.1111/jdv.19391.Pereyra-Rodriguez JJ, Herranz P, Figueras-Nart I, Perez B, Elosua M, Munera-Campos C et al. Treatment of Severe Atopic Dermatitis With Upadacitinib in Clinical Practice: Short-Term Efficacy and Safety Results. J Investig Allergol Clin Immunol. 2023;33(3):211–213. https://doi.org/10.18176/jiaci.0831.Pereyra-Rodriguez JJ, Herranz P, Figueras-Nart I, Perez B, Elosua M, Munera-Campos C et al. Treatment of Severe Atopic Dermatitis With Upadacitinib in Clinical Practice: Short-Term Efficacy and Safety Results. J Investig Allergol Clin Immunol. 2023;33(3):211–213. https://doi.org/10.18176/jiaci.0831.Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, Pink AE et al. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. N Engl J Med. 2021;384(12):1101–1112. https://doi.org/10.1056/NEJMoa2019380.Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, Pink AE et al. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. N Engl J Med. 2021;384(12):1101–1112. https://doi.org/10.1056/NEJMoa2019380.Gao Q, Zhao Y, Zhang J. Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. Heliyon. 2023;9(6):e16704. https://doi.org/10.1016/j.heliyon.2023.e16704.Gao Q, Zhao Y, Zhang J. Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. Heliyon. 2023;9(6):e16704. https://doi.org/10.1016/j.heliyon.2023.e16704.Porter E, O’Connor C, Murphy M. Re-engagement, quality of life, and burden of treatment in adults on dupilumab for severe atopic dermatitis-A mixed methods study. Skin Health Dis. 2024;4(4):e372. https://doi.org/10.1002/ski2.372.Porter E, O’Connor C, Murphy M. Re-engagement, quality of life, and burden of treatment in adults on dupilumab for severe atopic dermatitis-A mixed methods study. Skin Health Dis. 2024;4(4):e372. https://doi.org/10.1002/ski2.372.Stölzl D, Sander N, Heratizadeh A, Haufe E, Harder I, Abraham S et al. Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry. Br J Dermatol. 2022;187(6):1022–1024. https://doi.org/10.1111/bjd.21794.Stölzl D, Sander N, Heratizadeh A, Haufe E, Harder I, Abraham S et al. Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry. Br J Dermatol. 2022;187(6):1022–1024. https://doi.org/10.1111/bjd.21794.Barei F, Calzari P, Valtellini L, Chiei Gallo A, Perego G, Tavecchio S et al. Fiveyear real-world drug survival of dupilumab in severe atopic dermatitis and associate predictors. J Dermatolog Treat. 2024;35(1):2404718. https://doi.org/10.1080/09546634.2024.2404718.Barei F, Calzari P, Valtellini L, Chiei Gallo A, Perego G, Tavecchio S et al. Fiveyear real-world drug survival of dupilumab in severe atopic dermatitis and associate predictors. J Dermatolog Treat. 2024;35(1):2404718. https://doi.org/10.1080/09546634.2024.2404718.Kimball AB, Delevry D, Yang M, Chuang CC, Wang Z, Bégo-Le-Bagousse G et al. Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study. Dermatol Ther. 2023;13(9):2107–2120. https://doi.org/10.1007/s13555-023-00965-5.Kimball AB, Delevry D, Yang M, Chuang CC, Wang Z, Bégo-Le-Bagousse G et al. Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study. Dermatol Ther. 2023;13(9):2107–2120. https://doi.org/10.1007/s13555-023-00965-5.Sun Y, Liu H, Gao Y, Sang H, Kong Q. Effects of dupilumab on quality of life in patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2025;16:1587977. https://doi.org/10.3389/fphar.2025.1587977.Sun Y, Liu H, Gao Y, Sang H, Kong Q. Effects of dupilumab on quality of life in patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2025;16:1587977. https://doi.org/10.3389/fphar.2025.1587977.

The authors declare that there are no conflicts of interest present.